Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet’s signaling cascades as new outcome measures in clinical trials
David Pellerin(Université de Sherbrooke), François Corbin(Université de Sherbrooke), Mathieu Fradet(Université de Sherbrooke), Artuela Çaku(Université de Sherbrooke), P Bouvier(Université de Sherbrooke), Jean Y. Dubé(Université de Sherbrooke)
Cited by 50
Related Papers
Deep Intronic <i>FGF14</i> GAA Repeat Expansion in Late-Onset Cerebellar Ataxia
|New England Journal of Medicine|2022|243
GAA-<i>FGF14</i> ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response
|Brain|2023|114
Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open‐label study
|American Journal of Medical Genetics Part A|2014|78
Optimized testing strategy for the diagnosis of GAA-FGF14 ataxia/spinocerebellar ataxia 27B
|Scientific Reports|2023|72
Spinocerebellar ataxia 27B: A novel, frequent and potentially treatable ataxia
|Clinical and Translational Medicine|2024|71